RECRUITING

Angiotensin-(1-7) Cardiovascular Effects in Aging

Talk to us

Conditions

Agingcardiovascularblood pressureautonomic nervous systemrenin-angiotensin systemendothelial

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Aging is an independent risk factor for developing hypertension and cardiovascular disease; however, the mechanisms underlying age-related cardiovascular disease remain poorly understood. One hallmark of aging is an increase in sympathetic nervous system activity, which can decrease the number and/or sensitivity of β2 adrenergic receptors to reduce dilation of blood vessels and increase blood pressure. Identifying new targets to restore vascular β2 adrenergic receptor signaling may help reduce cardiovascular risk in aging. This study will test the hypothesis that angiotensin-(1-7), a protective hormone of the renin-angiotensin system, can reduce cardiovascular sympathetic outflow and blood pressure and improve endothelial function in older healthy humans.

Official Title

Angiotensin-(1-7) Cardiovascular Effects in Aging

Quick Facts

Study Start:2022-12-09
Study Completion:2025-12
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05301192

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:65 Years to 80 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Men and women of all races and ethnicities
  2. * Capable of giving informed consent
  3. * Fluent in written and spoken English
  4. * Age 65-80 years
  5. * Body mass index (BMI) between 18.5 and 30 kg/m2
  6. * Normotensive defined as seated blood pressure \<130/80 mmHg and without hypertensive medications
  7. * Satisfactory history and physical exam
  1. * Age \< 65 or \> 80 years
  2. * Women who are pregnant, nursing, or taking hormone replacement therapy
  3. * Decisional impairment
  4. * Prisoners
  5. * Current or recent (less than 6 months) recreational drug history or excessive alcohol abuse history (greater than 14 drinks per week)
  6. * Current smokers
  7. * Highly trained athletes
  8. * Evidence of type I or type II diabetes (fasting glucose \> 126 mg/dL or use of anti-diabetic medications)
  9. * Hypertension or history of serious cardiovascular disease (e.g., myocardial infarction within 6 months, symptomatic coronary artery disease, presence of angina pectoris, significant arrhythmia, congestive heart failure, deep vein thrombosis, pulmonary embolism, second or third degree heart block, mitral valve stenosis, aortic stenosis, hypertrophic cardiomyopathy) or cerebrovascular disease (e.g., cerebral hemorrhage, stroke, transient ischemic attack).
  10. * History or presence of immunological or hematological disorders
  11. * Impaired hepatic function \[aspartate aminotransferase (AST) or alanine aminotransferase (ALT) levels \>2 times upper limit of normal range\]
  12. * Impaired renal function (serum creatinine \>2.0 mg/dl)
  13. * Anemia
  14. * Taking drugs known to influence sympathetic activity (e.g. serotonin-norepinephrine reuptake inhibitors, norepinephrine transporter inhibitors, stimulants).
  15. * Treatment with anticoagulants (e.g. warfarin)
  16. * Treatment with chronic systemic glucocorticoid therapy (\>7 consecutive days in 1 month in the 1-month preceding the study)
  17. * Treatment with any investigational drug in the 1-month preceding the study
  18. * Known allergy or contraindication to angiotensin converting enzyme inhibitors or angiotensin receptor blockers, both of which increase endogenous angiotensin-(1-7) levels as part of their mechanism of action
  19. * Inability to give, or withdraw, informed consent

Contacts and Locations

Study Contact

Aimee Cauffman, RN
CONTACT
717-531-1617
acauffman@pennstatehealth.psu.edu
Amy Arnold, PhD
CONTACT
717-531-3674
aarnold5@pennstatehealth.psu.edu

Principal Investigator

Amy Arnold, PhD
PRINCIPAL_INVESTIGATOR
Pennsylvania State University College of Medicine

Study Locations (Sites)

Penn State Milton S. Hershey Medical Center
Hershey, Pennsylvania, 17033
United States

Collaborators and Investigators

Sponsor: Milton S. Hershey Medical Center

  • Amy Arnold, PhD, PRINCIPAL_INVESTIGATOR, Pennsylvania State University College of Medicine

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-12-09
Study Completion Date2025-12

Study Record Updates

Study Start Date2022-12-09
Study Completion Date2025-12

Terms related to this study

Keywords Provided by Researchers

  • cardiovascular
  • blood pressure
  • autonomic nervous system
  • renin-angiotensin system
  • endothelial

Additional Relevant MeSH Terms

  • Aging